Alto Neuroscience, a clinical-stage biopharmaceutical company based in Los Altos, California, focuses on developing psychiatric drugs using its Precision Psychiatry Platform. The company has five clinical-stage assets targeting depression and schizophrenia, with an IPO on February 2, 2024.
ANRO filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Tue, May 21, 2024. The patent was officially published on Thu, September 19, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
